Welcome to our dedicated page for GoodRx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
McGinnis Christopher A reported multiple insider transaction types in a Form 4 filing for GDRX. The filing lists transactions totaling 411,039 shares at a weighted average price of $2.18 per share. Following the reported transactions, holdings were 537,359 shares.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity award activity involving Class A common stock. On February 15, 2026, Nabiey exercised 4,804 restricted stock units, converting them into the same number of Class A shares at an exercise price of $0. In a related transaction coded "F," 1,979 Class A shares at $2.18 per share were disposed of to cover tax obligations, leaving 175,748 Class A shares held directly and 57,650 restricted stock units outstanding after these transactions.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported RSU vesting and related share movements. On February 8, 2026, 12,663 restricted stock units converted into 12,663 shares of Class A common stock at an exercise price of $0.
On the same date, a Form 4 code “F” transaction reported the disposition of 5,215 Class A shares at $2.44 per share. Following these transactions, Nabiey beneficially owned 172,923 Class A common shares directly and 63,314 restricted stock units, each representing a right to receive one Class A share.
GoodRx Holdings director Scott Wagner reported the vesting of deferred stock units and corresponding common stock on January 21, 2026. A deferred stock unit award vested for 31,394 units, which corresponds to 31,394 shares of Class A common stock at an exercise price of $0. After this transaction, Wagner directly beneficially owned 62,788 deferred stock units and 216,663 shares of Class A common stock. The deferred stock units will settle in shares on the earliest of December 31, 2030, separation from service, a change in control, death, or disability, under the company’s Deferred Compensation Plan for Directors.
GoodRx Holdings director and officer Wendy Lynn Barnes reported equity compensation activity involving restricted stock units and Class A common stock on January 15, 2026. A total of 665,302 restricted stock units were converted into the same number of Class A shares at an exercise price of $0.00 per share.
To cover tax obligations, 148,383 shares and 88,926 shares of Class A common stock were withheld at a price of $2.75 per share, reducing the net shares retained. After these transactions, Barnes directly beneficially owned 427,993 shares of GoodRx Class A common stock. Footnotes explain that each restricted stock unit represents a contingent right to receive one Class A share and outline multi-year vesting schedules for the awards.
GoodRx Holdings, Inc. disclosed that its board approved retention bonus letter agreements for Chief Executive Officer and President Wendy Barnes and Chief Financial Officer and Treasurer Chris McGinnis on December 9, 2025. Through these agreements, Ms. Barnes is eligible for a cash retention bonus of $2,000,000 and Mr. McGinnis for $1,000,000, each payable within 15 days after signing.
The bonuses must be repaid if employment ends either by the executive without "good reason" or by the company for "cause": 100% of the after-tax bonus if termination occurs on or before December 31, 2026, or 50% if termination occurs between January 1, 2027 and December 31, 2027. In exchange, both executives will forfeit any payment under the company’s 2025 executive bonus plan and any other 2025 annual cash incentive or discretionary bonus program. The full agreements are filed as Exhibits 10.1 and 10.2.
GoodRx Holdings, Inc. officer Romin Nabiey, the Chief Accounting Officer, reported equity transactions dated December 8, 2025. He acquired 10,200 and 2,232 shares of Class A common stock through the vesting and settlement of restricted stock units and disposed of 3,650 and 799 shares at $2.71 per share.
After these transactions, Nabiey directly beneficially owns 165,475 shares of Class A common stock. He also continues to hold restricted stock units representing 30,603 and 20,091 underlying shares, which vest 6.25% initially and then in approximately equal quarterly installments over 15 quarters starting on December 8, 2022 and June 8, 2024, respectively.
GoodRx Holdings, Inc. (GDRX) Chief Accounting Officer Romin Nabiey reported equity award activity on 11/15/2025. He acquired 4,804 shares of Class A common stock upon the vesting and settlement of restricted stock units and then disposed of 1,719 shares at $2.97 per share, typically used to cover taxes. Following these transactions, he directly held 156,492 Class A shares.
The underlying restricted stock unit grant covers 4,804 shares. It vests as to 6.25% of the underlying shares on May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over the next 15 quarters.
GoodRx Holdings (GDRX) reported an insider transaction by Chief Accounting Officer Romin Nabiey on 11/08/2025. Restricted stock units converted into 12,662 shares of Class A common stock (code M). To cover taxes, 4,531 shares were withheld at $3.11 per share (code F). Following these transactions, Nabiey directly owns 153,407 Class A shares. The filing also shows 75,977 RSUs remaining beneficially owned after the reported activity. Each RSU represents the right to receive one share, with vesting that began on August 8, 2023 and continues in approximately equal quarterly installments thereafter.
GoodRx Holdings, Inc. (GDRX) reported an insider transaction by a director. On 11/08/2025, 21,691 shares of Class A common stock were acquired via the conversion of deferred stock units (transaction code M).
After the transaction, the director beneficially owned 111,025 shares directly and held 43,384 deferred stock units. The filing notes the award vested as to one-third on November 8, 2025, and that deferred stock units will settle upon specified events, including December 31, 2029 or separation from service.